Clinical Trials
139 trialsRAVEN
UNC Lineberger Comprehensive Cancer Center
FORWARD
CareDx
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Children's Oncology Group
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
FT-RIC-HAPLO
Institut Paoli-Calmettes
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
City of Hope Medical Center
REVIVAL
AbbVie
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PREeMPT
Medical College of Wisconsin
Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)
University of Utah
QiNKT-HSCT
University Hospital Pilsen
Menin-Inhibitor Targeted Maintenance in AML
Center for International Blood and Marrow Transplant Research
TBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
ENKLA-M
Nantes University Hospital
MATCH-Treg
University Of Perugia
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
OHSU Knight Cancer Institute
MYELO-CAN:ABX
University of Manitoba
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
University of Miami
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
ABC-Maint
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Dana-Farber Cancer Institute
ThINKK-01
St. Justine's Hospital
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Northside Hospital, Inc.
VHAG
First People's Hospital of Hangzhou
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
The Children's Hospital of Zhejiang University School of Medicine
VENP-A-QUI
PETHEMA Foundation
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Fred Hutchinson Cancer Center
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
GRACE
University of Manchester
MIVONU
French Innovative Leukemia Organisation
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.